Design, synthesis, and biological evaluation of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives as anticancer agents
作者:Ayoub Aghcheli、Mahsa Toolabi、Adileh Ayati、Setareh Moghimi、Loghman Firoozpour、Tayebeh Oghabi Bakhshaiesh、Elahe Nazeri、Maryam Norouzbahari、Rezvan Esmaeili、Alireza Foroumadi
DOI:10.1007/s00044-020-02616-2
日期:2020.11
proliferation of tested cancer cells. In particular, 2-F, 4-Cl, and 2,6-diF substituted derivatives (5d, 5g, and 5k) showed promising activities, especially against Hela cancer cells (IC50 = 0.37, 0.73 and 0.95 µM, respectively) which were significantly more potent than sorafenib as the reference drug (IC50 = 7.91 µM). Flow cytometry analysis revealed that the prototype compounds (5d, 5g, and 5k) significantly
设计并合成了一系列新型的1-(5-(苄硫基)-1,3,4-噻二唑-2-基)-3-苯基脲衍生物(5a-1)作为索拉非尼类似物。评价了合成化合物对四种不同的人类癌细胞(包括MCF-7,HepG2,A549和HeLa细胞系)的体外细胞毒性作用。生物学结果表明,大多数化合物显着阻止了测试癌细胞的增殖。特别是2-F,4-Cl和2,6- di F取代的衍生物(5d,5g和5k)显示出有希望的活性,尤其是针对Hela癌细胞(IC 50 分别为0.37、0.73和0.95 µM),这比索拉非尼作为参考药物的效用要强得多(IC 50 = 7.91 µM)。流式细胞仪分析表明,原型化合物(5d,5g和5k)显着诱导HeLa癌细胞凋亡,并阻止了亚G1期的细胞周期。此外,计算机对接研究证实了原型化合物与VEGFR-2活性位点的结合。